Related Experiment Videos
Possible ciprofloxacin-induced acute cholestatic jaundice
1St. John's University College of Pharmacy, Jamaica, NY 11439.
The Annals of Pharmacotherapy
|October 1, 1994
Summary
This case report details a rare instance of acute cholestatic jaundice linked to ciprofloxacin, an antibiotic. Promptly discontinuing the drug led to the patient
Area of Science:
- Hepatology
- Pharmacology
- Infectious Diseases
Background:
- Ciprofloxacin is a widely used fluoroquinolone antibiotic for treating bacterial infections.
- Drug-induced liver injury (DILI) is a significant concern in clinical practice.
- Cholestatic jaundice, characterized by impaired bile flow, can manifest with various etiologies.
Observation:
- An 84-year-old female developed acute cholestatic jaundice during ciprofloxacin treatment for a urinary tract infection.
- The patient presented with jaundice, elevated liver enzymes, and hypercholesterolemia.
- A rash was noted, prompting discontinuation of ciprofloxacin due to suspected allergy.
Findings:
- Liver function tests normalized within one month after ciprofloxacin cessation.
- The patient recovered fully, with normal liver function tests at three months follow-up.
- This case adds to the limited literature on ciprofloxacin-induced cholestatic liver injury.
Implications:
- Clinicians should consider ciprofloxacin as a potential cause of cholestatic jaundice.
- Monitoring liver function is advisable in patients receiving ciprofloxacin, especially those with risk factors.
- Further research is needed to elucidate the mechanisms of fluoroquinolone-induced hepatotoxicity.